丙型肝炎病毒职业暴露后预防:为何直接抗病毒药物不改变现状
美国每年发生38万至40万次血源性病原体职业暴露;HIV和HBV暴露可酌情使用暴露后预防(PEP),但HCV暴露不推荐PEP。尽管直接抗病毒药物(DAA)获批后有人讨论将其用于HCV暴露后预防,但尚无发表研究支持这一做法,且已有处方DAA用于PEP的报道。本文讨论三种常见血源性病原体传播差异、早期HCV感染自然史及PEP科学依据,并指出开展DAA用于PEP的充分把握度临床试验可行性低、成本效益差,不支持将有限资源用于此目的。
要点
- HCV职业暴露后不推荐使用PEP,包括直接抗病毒药物。
- DAA用于HCV暴露后预防缺乏已发表研究证据。
- 开展DAA用于PEP的临床试验可行性低且成本效益差。
核心结论
- 直接抗病毒药物不改变HCV职业暴露后不推荐PEP的现状。
研究设计与样本
- 本文为叙述性综述,讨论血源性病原体传播、早期HCV感染自然史及PEP科学依据。
主要发现
- 美国每年发生38万至40万次血源性病原体职业暴露。
- HIV或HBV职业暴露必要时可进行PEP,但HCV暴露不推荐PEP。
- 已有处方DAA用于HCV暴露后预防的报道,但尚无发表研究探讨该问题。
临床怎么用
- HCV职业暴露后不应常规处方DAA进行暴露后预防。
局限性
- 缺乏DAA用于HCV暴露后预防的已发表研究证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Currently, 380 000-400 000 occupational exposures to blood-borne pathogens occur annually in the United States. The management for occupational HIV or hepatitis B virus exposures includes postexposure prophylaxis (PEP) when necessary; however, PEP is not recommended for hepatitis C virus (HCV) exposures. Recent approval of HCV direct-acting antivirals (DAAs) has renewed discussions as to whether these therapies could be used to prevent infection after exposure. There are no published studies addressing this question, but the prescribing of DAAs for PEP has been reported. We will discuss the differences in transmission of the 3 most common blood-borne pathogens, the natural history of early HCV infection, and the scientific rationale for PEP. In particular, we will discuss how the low feasibility of conducting an adequately powered clinical trial of DAA use for PEP and the low cost-effectiveness of such an intervention is not supportive of targeting limited resources for such use.
引用
- Naggie S, Holland DP, Sulkowski MS, et al. Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing. Clin Infect Dis. 2016. PMID: 27682067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。